{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:00:16Z","timestamp":1790308816574,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As immunotherapy becomes entrenched in the frontline management of advanced NSCLC, post-progression treatment decisions face increasing uncertainty. A recent JAMA Network Open study using Flatiron Health data suggested that rechallenging with pembrolizumab may offer survival benefit after chemo immunotherapy progression. However, these findings raise fundamental questions about how real-world data (RWD) should be interpreted and operationalized in health economics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main argument<\/jats:title>\n                    <jats:p>In this viewpoint, we critically analyze the methodological and interpretive assumptions behind retrospective RWD-based cost-effectiveness modeling. We argue that unadjusted survival metrics absent stratification for PD-L1 status, tumor burden, or clinical performance may artificially elevate ICER\/QALY estimates and misguide reimbursement decisions. Using the Velcheti et al. study as a case anchor, we highlight how structural biases in RWD can lead to premature or inflated conclusions about the value of immunotherapy rechallenge. We also propose a visual framework to distinguish between plausible clinical signals and policy-grade evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications<\/jats:title>\n                    <jats:p>Health systems and stakeholders must apply greater rigor when translating RWD into economic models. We advocate for analytic transparency, pre-registered sensitivity analyses, and adjustment for patient-level variables before using RWD to inform value-based oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>RWD are powerful hypothesis generators, not substitutes for controlled evidence. Without methodological discipline, their policy application risks becoming speculative rather than strategic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag106","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:07:43Z","timestamp":1777637263000},"source":"Crossref","is-referenced-by-count":0,"title":["Cost, context, and confounding: rethinking real-world data generation and interpretation in advanced NSCLC"],"prefix":"10.1093","volume":"31","author":[{"given":"Mehmet Mutlu","family":"\u00c7atl\u0131","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Antalya Education and Research Hospital , Antalya 07090,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-5228","authenticated-orcid":false,"given":"Arif Hakan","family":"\u00d6nder","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antalya Education and Research Hospital , Antalya 07090,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026092423220585900_oyag106-B1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what \u0131s \u0131t and what can \u0131t tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"2026092423220585900_oyag106-B2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/cpt.857","article-title":"When and how can real world data analyses substitute for randomized controlled trials?","volume":"102","author":"Franklin","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2026092423220585900_oyag106-B3","doi-asserted-by":"publisher","first-page":"e2514527","DOI":"10.1001\/jamanetworkopen.2025.14527","article-title":"Treatments and outcomes after platinum-based chemotherapy and anti-PD-(L)1 in NSCLC","volume":"8","author":"Velcheti","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026092423220585900_oyag106-B4","doi-asserted-by":"publisher","first-page":"1034256","DOI":"10.3389\/frhs.2023.1034256","article-title":"Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: a systematic review and methodological quality assessment","volume":"3","author":"Zaim","year":"2023","journal-title":"Front Health Serv"},{"key":"2026092423220585900_oyag106-B5","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.37765\/ajmc.2021.88726","article-title":"Cost-effectiveness of nivolumab in patients with NSCLC in the United States","volume":"27","author":"Chaudhary","year":"2021","journal-title":"Am J Manag Care"},{"key":"2026092423220585900_oyag106-B6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092423220585900_oyag106-B7","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx187","article-title":"Real-world data for clinical evidence generation in oncology","volume":"109","author":"Khozin","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"2026092423220585900_oyag106-B8","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the prpensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"2026092423220585900_oyag106-B9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"2026092423220585900_oyag106-B10","volume-title":"Applied Methods of Cost-Effectiveness Analysis in Health Care","author":"Gray"},{"key":"2026092423220585900_oyag106-B11","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00262-020-02646-0","article-title":"Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation","volume":"69","author":"Couchoud","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2026092423220585900_oyag106-B12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jval.2019.01.001","article-title":"Health technology assessment challenges in oncology: 20 years of value in health","volume":"22","author":"Kim","year":"2019","journal-title":"Value Health"},{"key":"2026092423220585900_oyag106-B13","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1200\/JCO.2010.28.5478","article-title":"Rapid-learning system for cancer care","volume":"28","author":"Abernethy","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026092423220585900_oyag106-B14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/cancers16071414","article-title":"Real-world data and evidence in lung cancer: a review of recent developments","volume":"16","author":"Kokkotou","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026092423220585900_oyag106-B15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/cpt.512","article-title":"Real world data in adaptive biomedical \u0131nnovation: a framework for generating evidence fit for decision-making","volume":"100","author":"Schneeweiss","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2026092423220585900_oyag106-B16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.jval.2019.07.007","article-title":"Unmet medical need: an \u0131ntroduction to definitions and stakeholder perceptions","volume":"22","author":"Vreman","year":"2019","journal-title":"Value Health"},{"key":"2026092423220585900_oyag106-B17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41586-021-03430-5","article-title":"Evaluating eligibility criteria of oncology trials using real-world data and AI","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"2026092423220585900_oyag106-B18","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","article-title":"What \u0131s real-world data? A review of definitions based on literature and stakeholder \u0131nterviews","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"key":"2026092423220585900_oyag106-B19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/pds.4932","article-title":"Trial designs using real-world data: the changing landscape of the regulatory approval process","volume":"29","author":"Baumfeld Andre","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026092423220585900_oyag106-B20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making","volume":"26","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026092423220585900_oyag106-B21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"key":"2026092423220585900_oyag106-B22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nrd2664","article-title":"Balancing early market access to new drugs with the need for benefit\/risk data: a mounting dilemma","volume":"7","author":"Eichler","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"2026092423220585900_oyag106-B23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1470-2045(23)00007-4","article-title":"Accelerating cancer omics and precision oncology in health care and research: a Lancet Oncology Commission","volume":"24","author":"Casolino","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag106\/68209569\/oyag106.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag106\/68209569\/oyag106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag106\/68209569\/oyag106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:22:22Z","timestamp":1790306542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag106\/8667172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag106","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,5,4]]},"article-number":"oyag106"}}